| HOME >> BIOLOGY >> TECHNOLOGY |
Net loss $(9,051,670) $(13,770,095) $(42,249,366) $(41,990,154)
Basic and diluted
net loss per share $(0.19) $(0.44) $(0.96) $(1.38)
Shares used in
calculation of
basic and diluted
net loss per share 46,734,506 31,503,384 43,816,145 30,535,965
MIDDLEBROOK PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
December 31,
2007 2006
ASSETS
Current assets:
Cash and cash equivalents $1,951,715 $14,856,738
Marketable securities - 522,723
Accounts receivable, net 687,787 303,514
Inventories, net 687,933 2,077,390
Prepaid expenses and other
current assets 1,142,905 1,682,685
Total current assets 4,470,340 19,443,050
Property and equipment, net 10,928,659 11,764,627
Restricted cash 872,180 872,180
Deposits and other assets 174,965 1,548,585
Intangible assets, net 7,219,651 8,377,327
Total assets $23,665,795 $42,005,769
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable $1,659,752 $2,285,736
Accrued expenses and advances 5,613,544 7,817,224
Lines of credit and short term debt - 6,888,889
'/>"/>
| SOURCE MiddleBrook Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |